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Abstract
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (PDA) in
preterm infants, especially in those born at a gestational age (GA) less than 28 weeks. No causal relationship has
been proven between a (haemodynamically significant) PDA and neonatal complications related to pulmonary
hyperperfusion and/or systemic hypoperfusion. Although studies show conflicting results, a common
understanding is that medical or surgical treatment of a PDA does not seem to reduce the risk of major neonatal
morbidities and mortality. As the PDA might have closed spontaneously, treated children are potentially exposed to
iatrogenic adverse effects. A conservative approach is gaining interest worldwide, although convincing evidence to
support its use is lacking.
Methods: This multicentre, randomised, non-inferiority trial is conducted in neonatal intensive care units. The study
population consists of preterm infants (GA < 28 weeks) with an echocardiographic-confirmed PDA with a
transductal diameter > 1.5 mm. Early treatment (between 24 and 72 h postnatal age) with the cyclooxygenase
inhibitor (COXi) ibuprofen (IBU) is compared with an expectative management (no intervention intended to close a
PDA). The primary outcome is the composite of mortality, and/or necrotising enterocolitis (NEC) Bell stage ≥ IIa,
and/or bronchopulmonary dysplasia (BPD) defined as the need for supplemental oxygen, all at a postmenstrual age
(PMA) of 36 weeks. Secondary outcome parameters are short term sequelae of cardiovascular failure, comorbidity
and adverse events assessed during hospitalization and long-term neurodevelopmental outcome assessed at a
corrected age of 2 years. Consequences regarding health economics are evaluated by cost effectiveness analysis
and budget impact analysis.
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Discussion: As a conservative approach is gaining interest, we investigate whether in preterm infants, born at a GA
less than 28 weeks, with a PDA an expectative management is non-inferior to early treatment with IBU regarding to
the composite outcome of mortality and/or NEC and/or BPD at a PMA of 36 weeks.
Trial registration: This trial is registered with the Dutch Trial Register NTR5479 (registered on 19 October 2015), the
registry sponsored by the United States National Library of Medicine Clinicaltrials.gov NCT02884219 (registered May
2016) and the European Clinical Trials Database EudraCT 2017–001376-28.
Keywords: Prematurity, Patent ductus arteriosus, Neonatal intensive care unit, Ibuprofen, Expectative management,
Ductal ligation, Mortality, Necrotising enterocolitis, Bronchopulmonary dysplasia, Cost-effectiveness
Background
Controversy exists about the optimal management of a
patent ductus arteriosus (PDA) in preterm infants, espe-
cially in those born at a gestational age (GA) less than
28 weeks, due to a lack of evidence for any specific treat-
ment including non-intervention [1–12]. There is also
no consensus about the diagnostic criteria of a haemo-
dynamically significant PDA (hsPDA). The reported inci-
dence of a PDA in preterm infants is 30–60%,
depending on the used definition, the timing of the diag-
nosis and the studied population.
PDA has been associated with mortality and major mor-
bidities, such as bronchopulmonary dysplasia (BPD), pul-
monary haemorrhage (PH), intraventricular haemorrhage
(IVH), necrotising enterocolitis (NEC) and retinopathy of
prematurity (ROP). The underlying pathophysiologic
mechanism of this might be that a PDA with significant
left-to-right shunting results in pulmonary hyperperfusion
and systemic hypoperfusion, although any evidence for a
causal relationship is lacking [13–19].
There is a large variation in the management of a PDA
between centres [20–22]. Pharmacological closure of the
PDA is most often attempted by inhibition of prosta-
glandin synthesis with non-selective cyclooxygenase in-
hibitors (COXi), such as indomethacin (INDO) or
ibuprofen (IBU). By postponing the start of treatment of
a PDA, the risk of redundant adverse effects of COXi is
decreasing as the postnatal age (PNA) at which COXi is
started increases, while the time of exposure to a hsPDA
might be prolonged. Some reports suggest that a high
dose of IBU might be more effective in ductal closure in
preterm infants, especially in those less than 27 weeks’
gestation [23–26]. However, in a recent systematic re-
view Ohlsson et al. refrained from recommendations re-
garding high dose IBU because of the limited number of
patients enrolled in the studies [17]. Use of paracetamol
has been associated with closure of a PDA in studies
with only a limited number of preterm infants [27–35].
Moreover, the high dose of paracetamol (60 mg/kg/day)
that is used to close the PDA gives rise to concerns
about safety in preterm infants [36–38]. Standard
ligation after failure of medical closure resulted in an
increased incidence of BPD and neurodevelopmental im-
pairment in comparison with delayed ligation in a selected
population [39, 40]. Of interest, an expectative approach
after failure of treatment was followed by ‘spontaneous’
closure in 67–86% of the patients [39, 41, 42].
Roughly, there are four different management ap-
proaches for preterm infants with a PDA: (1) prophylac-
tic treatment; (2) pre-symptomatic (‘early’) treatment; (3)
symptomatic (‘late’) treatment and; (4) expectative
management [9, 12].
1. Prophylactic treatment consists of administration of
COXi in all patients within a predefined patient
group at a PNA less than 24 h. Prophylactic
administration of INDO has been shown to reduce
the incidence of symptomatic PDA, need for
surgical ligation, and severe cerebral haemorrhage,
and it seems to reduce the risk of PH [14, 43].
However, no effect was found on mortality or
neurodevelopmental outcome at the age of 18–
36 months [44]. Prophylactic IBU administration
reduced the need for additional treatment of the
PDA, but no effect has been described on the
incidence of severe comorbidity [16].
2. Pre-symptomatic treatment is usually timed within
the first 3 to 5 days of life. Significant left-to-right
shunting can already occur early after birth,
whereas clinical signs generally manifest later, with
an average delay of 2 days [45, 46]. Echocardiog-
raphy is used to identify patients with a potentially
increased risk of PDA-associated morbidity [47]. No
beneficial effects on relevant neonatal morbidity
were found in a systematic review of the adminis-
tration of INDO for asymptomatic PDA in preterm
infants [13].
3. In symptomatic treatment, physicians wait for a
possible spontaneous closure of the ductus
arteriosus (DA). Treatment is only started when
clinical signs and symptoms presumably related to a
PDA develop. As formulated by Evans ‘It is the
clinical approach that is most widely used but we do
not have any evidence to support it’ [9].
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4. Expectative management is characterized by
‘watchful waiting’ without the intention to actively
close the DA. This approach is based on the fact
that in a substantial portion of preterm infants the
DA will close spontaneously [9, 41, 42, 48–50] and
that there is a lack of proven benefit of medical
treatment [1–12]. This expectative approach to a
PDA in preterm infants is gaining interest. A recent
multicentre retrospective study in 28,025 very low
birth weight infants (< 1500 g) showed that the
annual rate of patients who were not treated for
their PDA (n = 12,002) increased from 60.5% in
2008 to 78.3% in 2014 [51].
Meta-analysis of randomised controlled trials evaluating
PDA treatment
We searched for all randomised controlled trials (RCTs)
evaluating PDA treatment in the US National Library of
Medicine (Medline), Cochrane Library, EMBASE and
ClinicalTrials.gov database, using the Mesh terms: ‘in-
fant, newborn’AND ‘ductus arteriosus, patent’, combined
with ‘indomethacin’ OR ‘ibuprofen’ OR ‘cyclooxygenase
inhibitors’ OR ‘paracetamol’. This search revealed a total
of 787 hits. We excluded non-randomised studies and
RCTs that are not placebo-controlled. Some eligible
studies had to be excluded due to language (non-E-
nglish) or unavailable full text. A total of 32 RCTs were
included in a systematic review [15, 18, 44, 52–80]. Data
on the outcome parameters were extracted independ-
ently by two reviewers (WO and WdB) and entered into
Review Manager Software for meta-analysis (Revman
version 5.3 Copenhagen: The Nordic Cochrane Centre,
The Cochrane Collaboration, 2014). Random effects
meta-analysis of the 32 included studies showed that,
when compared with placebo, COXi are effective in
ductal closure on the short term, since the risk ratio for
failure of ductal closure is 0.44 (0.38–0.50). However,
this was not associated with a reduction in mortality and
morbidity (Table 1).
Based on these data, it has been assumed that PDA
treatment, although it does lead to a higher rate of
ductal closure, does not lead to a significant better out-
come. However, critical analysis of the data shows that a
substantial part (up to 85%) of the control group was ac-
tually treated for PDA (Fig. 1). So, instead of concluding
that PDA treatment does not lead to a better outcome it
can only be concluded that there is no significant differ-
ence in early versus later or delayed treatment, due to
the high amount of treated infants in the control group.
Randomised controlled trials evaluating expectative
management
Until now, no RCT has been published that compares
treatment of a PDA with COXi with an expectative ap-
proach, i.e. no treatment intended to actively close the
PDA. Table 2 gives an overview of recent observational
studies describing the outcome of conservative manage-
ment, that were compared with the Vermont Oxford
Network database from 2009 [81–90]. Several studies
were excluded due to a high treatment rate in the con-
trol group with both INDO (up to 100%) and/or ligation
(up to 72%) [39, 91–94]. In addition, the conservative
management was rather heterogeneous, ranging from an
expectative management to fluid restriction, diuretics
and/or adapted ventilator settings. Therefore, although
these studies suggest that an expectative approach does
not seem to be associated with an increased incidence of
neonatal mortality or morbidity, convincing evidence
supporting this wait-and-see policy is still lacking, espe-
cially in preterm infants born at less than 28 weeks’
gestation.
Research gap
To date, no RCT has been published that compares early
treatment of a PDA with COXi in preterm infants less
than 28 weeks’ gestation with an expectative approach,
that is defined as no intervention in relation to the PDA.
Table 1 Meta-analysis of COXi versus placebo in preterm neonates with PDA
Outcome Studies Participants Risk Ratio 95%-CI
Mortality 31 3534 0.98 0.84–1.13
BPD (total) 23 3531 1.07 0.98–1.16
BPD (oxygen need at PNA 28 days) 16 1395 1.07 0.94–1.22
BPD (oxygen need at PMA 36 weeks) 8 2136 1.06 0.95–1.20
NEC 23 3285 1.05 0.83–1.32
Death or BPD at PMA 36 weeks 7 2096 1.05 0.97–1.14
IVH 20 3150 0.98 0.88–1.10
Failure of ductal closure 23 1619 0.44 0.38–0.50
CI, Confidence interval; BPD, Bronchopulmonary dysplasia; PNA, Postnatal age; PMA, Postmenstrual age; NEC, Necrotising enterocolitis (any grade); IVH,
Intraventricular haemorrhage (any grade)
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Methods/design
Study aims
Our aim is to investigate whether in preterm infants,
born at a GA less than 28 weeks, with a PDA (diam-
eter > 1.5 mm) at a PNA < 72 h, an expectative manage-
ment is non-inferior to early treatment with regard to
the composite of mortality and/or NEC (Bell stage ≥ IIa)
and/or BPD at a postmenstrual age (PMA) of 36 weeks.
Study design and settings
Multicentre, randomised, non-inferiority trial conducted
in level III neonatal intensive care units (NICUs) in
Europe (BeNeDuctus trial). A flow chart of the study de-
sign is shown in Fig. 2.
Ethical consideration
After analysis of the results from many RCTs it has been
concluded that treatment of a PDA does not result in a
decreased rate of mortality and morbidity. A conserva-
tive approach towards a PDA is increasingly used in
many centres worldwide without a concomitant increase
in mortality or morbidity [51, 81–89, 95]. The adminis-
tration of IBU in the treatment arm of this trial does not
pose an extra burden on the patient as it is considered
routine treatment in preterm infants with a PDA in
many NICUs. Patients who are not treated with IBU are
refrained from potential adverse effects of this drug. All
patients in this study are treated in accordance with
current (inter)national guidelines and local protocols re-
garding neonatal intensive care management. All pri-
mary and secondary outcome parameters are evaluated
as part of routine care in Belgium and the Netherlands.
No extra investigations, apart from the blinded echocar-
diogram in the expectative treatment arm, or interven-
tions are needed in this study. Gentle handling of the
preterm during echocardiography has been shown not
to disturb cardiorespiratory stability [96, 97].
Definitions
Transductal diameter of a PDA is measured as described
by Kluckow and Evans [98]. Of note, the inclusion criter-
ion of a transductal diameter > 1.5 mm is not meant to
define hemodynamic significance. It is only used to ex-
clude randomisation of preterm infants with a nearly
closed DA. A DA is considered to be closed when the
transductal diameter measures less than 0.5 mm or it
cannot be visualized using colour Doppler imaging. NEC
is classified according to the modified Bell staging cri-
teria [99]. BPD is defined as the need for supplemental
oxygen at a PMA of 36 weeks and diagnosed following
international standard criteria by Bancalari, including an
oxygen reduction test according to Walsh [100, 101].
Fig. 1 Percentage of patients in the control group eventually treated for their PDA
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Hypotension is defined as a mean arterial blood pressure
less than the gestational age in weeks. IVH is classified
according to the classification by Volpe [102]. Periven-
tricular echogenicity is classified according to the classi-
fication by Hashimoto et al. [103]. Sepsis is defined as a
positive blood culture for which the patient has been
treated with antibiotics. ROP is classified according to
the international classification [104].
Preterm infants born at a GA of less than 28 weeks,
admitted to a level III NICU, both inborn and outborn,
are eligible.
Inclusion criteria are (1) preterm infants born at a
GA < 28 weeks; (2) PNA between 24 and 72 h; (3) PDA
diameter > 1.5 mm and predominantly left-to-right
transductal shunt (≥ 66% of the cardiac cycle); and (4)
signed informed consent obtained from parent(s) or rep-
resentative(s). Exclusion criteria are (1) contraindica-
tion(s) for the administration of IBU (e.g. active
bleeding, especially intracranial or gastrointestinal haem-
orrhage; thrombocytopenia (< 50x10E9/L); renal failure
(raised creatinine (> 120 μmol/L) or oliguria (< 0.5 mL/
kg/h)); known or suspected NEC); (2) use of COXi prior
to randomisation; (3) persistent pulmonary hypertension
(ductal right-to-left shunt ≥33% of the cardiac cycle); (4)
congenital heart defect, other than PDA and/or patent
foramen ovale; (5) life-threatening congenital defects or;
(6) chromosomal abnormalities and/or congenital
anomalies associated with abnormal neurodevelopmental
outcome.
Primary outcome definition
The primary endpoint is the composite of mortality,
and/or NEC (Bell stage ≥ IIa), and/or BPD at a PMA of
36 weeks.
Secondary outcome definition
During the first eleven postnatal days there will be a
daily recording in the electronic Case Report Form
(eCRF) of the following, first available parameters in the
morning: (a) blood pressure (systolic, diastolic and mean
pressure) in mmHg; (b) heart rate in beats per minute;
(c) urine output in mL/kg/h in the last 8–12 h; (d) actual
weight in grams; (e) total daily fluid intake in mL/kg/
24 h and; (f ) total enteral intake in mL/kg/24 h.
Secondary endpoints are divided in three categories:
1. Short term sequelae of cardiovascular failure, such
as (a) hypotension and; (b) need for cardiovascular
support.
2. Adverse events during hospitalization, such as (a)
BPD at a PNA of 28 days; (b) mortality at a PNA of
28 days and at hospital discharge; (c) modes and
duration of respiratory support; (d) total days of
oxygen supplementation; (e) incidence of
Fig. 2 Flow chart of the study design. COXi, cyclo-oxygenase inhibitor; DA, Ductus arteriosus; DOL, day of life; GA, gestational age; (hs)PDA,
(Haemocyamic significant) patent ductus arteriosus; PNA, postnatal age
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pulmonary air leakage (e.g. pneumothorax); (f ) PH;
(g) IVH; (h) periventricular echogenicity; (i) NEC;
(j) gastrointestinal bleeding; (k) spontaneous
intestinal perforation; (l) time to full enteral feeding;
(m) sepsis; (n) ROP; (o) adverse effects of IBU; (p)
need for surgical ligation of PDA and; (q) length of
hospitalization.
3. Neurodevelopmental outcome is assessed in all
Dutch and Belgian children in the National
Neonatal Follow Up Program at a corrected age of
24 months by (a) paediatric and neurologic
examination; (b) cognitive assessment with Bayley
Scales of Infant and Toddler Development, Third
Dutch Edition (BSID-III-NL); (c) behavioural
assessment with Child Behavior Check List (CBCL),
Teacher Report Form (TRF) questionnaire and; (d)
motor function with Movement Assessment Battery
for Children, Second Dutch Edition (Movement
ABC 2-NL). For non-Dutch or Belgian children
equivalent assessments may be used.
Economic evaluation
The economic evaluation is performed along-side the
randomised clinical study. We will conduct both a
cost-effectiveness analysis (CEA) and a budget impact
analysis (BIA).
Cost-effectiveness analysis
The potential efficiency of expectative management of
PDA in preterm infants with a PDA is compared to the
heterogeneous usual care for preterm infants with a
PDA. The CEA is performed from a societal perspective.
We hypothesize that expectative management is the
cost-effective alternative, because it saves on medical
treatments and diagnostics at non-inferior effectiveness.
The economic evaluation is based on the general princi-
ples of a CEA. Primary outcome measures for the eco-
nomic evaluation, considering the 24 months follow-up
period, are (in)direct costs and composite of survival
and/or NEC and/or BPD. When this composite does not
differ between an expectative management and usual
care the cost-effectiveness decision rule will be cost
minimization, else it will be cost associated with a gain
or loss in survival and/or NEC and/or BPD. This effi-
ciency outcome will be computed and uncertainty will
be determined using the bootstrap method. If a differ-
ence between the two alternative treatments occurs, a
cost-effectiveness acceptability curve will be derived that
is able to evaluate efficiency by using different thresholds
(Willingness To Pay) for a combined survival effect. The
impact of uncertainty surrounding deterministic param-
eters on the efficiency outcome will be explored using
one-way sensitivity analyses on the range of extremes.
The cost analysis exists of two main parts. First, on pa-
tient level, volumes of care will be measured prospect-
ively over the time path of the clinical study using the
eCRF and/or medical records and the inpatient treat-
ment facilities administration system to collect informa-
tion on for example: consultation paediatric cardiologist,
echocardiography, chest X-ray, medication, intensive
care transport and ductal ligation. Second per arm full
cost-prices will be determined using the Dutch guideline
[105], or else real cost prices via activity based costing or
centre-specific cost information. Productivity losses for
parents will be estimated using a patient-based iMTA
Productivity Cost Questionnaire adapted to parents at a
postnatal age of 4 weeks and a corrected age of 6, 12
and 24 months [106]. The questionnaire is given to the
parents by mail together with a post-paid envelope or
sent via electronic mail. The friction cost-method will be
applied following the Dutch guidelines [105]. The cost
analysis will be performed using a mixed model ap-
proach with centre as random coefficient and potential
confounders as fixed.
Budget impact analysis
The aim of this BIA is to assess the financial consequences
of implementing an expectative management in the Dutch
health care system in the short-to-medium term from the
budget holder’s perspective [107]. The BIA base-case per-
spectives are respectively societal, health insurance/third
party payer and health care. A global average cost per pa-
tient for expectative management is €89,000 and for the
usual care €92,000. Multiplied by the yearly number of
preterm neonates with a PDA in the Netherlands (n =
270) gives a global impression of the magnitude of the
budget impact, namely €24,000,000 compared to
€24,800,000. This provides a yearly budgetary saving of
about €800,000. At least four scenarios will be considered,
namely (1) current care; (2) immediate 100% expectative
management; (3) gradual implementation of expectative
management and; (4) partial implementation of expecta-
tive management. The BIA will be assessed through (deci-
sion analytical) modelling and analysed, if possible, in a
probabilistic way [108].
Randomisation process
In the absence of exclusion criteria, eligible patients will
be randomised to either the expectative management arm
or the medical treatment arm. The randomisation is coor-
dinated centrally and web-based. Randomisation will be
per centre and stratified according to GA stratum
(Stratum A: GA < 260/7 weeks; Stratum B: GA 260/7–276/7
weeks). The block size will vary in a range from four to
eight. The intention is to randomise multiple birth infants
independently, unless there is an explicit request from the
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parents/caretakers to expose the siblings to the same
treatment.
Withdrawal and replacement of individual subjects
The investigator or attending physician can decide to
withdraw a subject from the study for urgent medical
reasons. If they wish, parents or caregivers can leave the
study at any time for any reason. Only patients that are
withdrawn from the study at the request of parents or
caregivers will be replaced. The total number of patients
that can be replaced is limited to twenty-five. Infants
who are withdrawn from the study, will receive standard
of care, including regular follow up after discharge, with
assessment of neurodevelopmental outcome. Patients in
the expectative management arm that meet the criteria
for open label treatment with IBU (Table 3) and/or sur-
gical ligation (Table 4) will remain in follow up and are
therefore not withdrawn from the study.
Treatment arms
Expectative management arm (intervention)
Patients randomised to the expectative management arm
will not receive COXi, including for indications other
than closure of the DA. No (additional) putative inter-
ventions to prevent or treat a PDA, for example fluid re-
striction or diuretics for that purpose only, are allowed.
When the attending physician thinks that the patient is
in danger when being deprived from treatment with
COXi, open label treatment can only be considered
when pre-specified criteria are met (Table 3). To be in-
formed about the natural course of ductal closure echo-
cardiography is performed at the end of the first week of
life, but only when it is feasible for the clinical team to
remain blinded for the results.
Medical treatment arm (control)
Patients in the medical treatment arm receive COXi as
soon as possible after randomisation, preferably within
3h. In this study IBU is used, because it seems to be as
effective in ductal closure in preterm infants as INDO.
Besides, IBU might have less side-effects than INDO,
since IBU reduces the risk of NEC and transient renal
insufficiency [17], does not affect mesenteric blood flow,
has less effect on renal perfusion [109–111], and influ-
ences cerebral blood flow in a lesser extent [111–114].
The dosing scheme for IBU is according to local guide-
lines. The preferred route of administration of IBU is
intravenously. However, this is at the discretion of the
attending physician, since enteral administration appears
at least as effective [17, 115–118].
Echocardiographic re-evaluation is performed at
least 12h after the last (third) dose of the first IBU
course. If the DA is found to be closed, no further
analysis or treatment is needed regarding the DA.
When the DA has not closed, a second course of IBU
is started at least 24h after the third dose of the first
course, in a similar dosage. 12 to 24h after the last
(sixth) dose of the second course echocardiography is
performed again. If the DA is found to be closed, no
further analysis or treatment is needed regarding the
DA. When the DA failed to close after two courses of
IBU and is still classified as a hsPDA, ductal ligation
can be considered, when the ligation criteria are met
(Table 4).
Table 3 Open label criteria
I. Exclusion of other causes of cardiovascular failure (e.g. sepsis or
congenital heart defect)
AND
II. Clinical findings of cardiovascular failure secondary to significant
ductal left-to-right shunting:
a. Signs of systemic hypoperfusion (refractory systemic
hypotension and/or elevated serum lactate concentration
(> 2.5 mmol/L)) and;
b. Signs of pulmonary hyperperfusion (prolonged ventilator
dependency).
AND
III. Echocardiographic findings of significant ductal left-to-right
shunting
a. Diameter of PDA > 1.5 mm, and;
b. Unrestricted ductal left-to-right shunting (‘pulsatile pattern’):
end-diastolic flow velocity < 50% of peak flow velocity, and;
c. End-diastolic flow velocity left pulmonary artery > 0.3 m/s, and;
d. Left atrial to aortic ratio > 1.5.
AND
a. Severe left ventricular failure (mitral regurgitation), and;
b. Disturbed end-organ perfusion (retrograde diastolic blood
flow in descending aorta).
Table 4 Ligation criteria
I. Exclusion of other causes of cardiovascular failure (e.g. sepsis or
congenital heart defect)
AND
II. Clinical findings of cardiovascular failure secondary to significant
ductal left-to-right shunting:
a. Signs of systemic hypoperfusion (refractory systemic
hypotension and/or elevated serum lactate concentration
(> 2.5 mmol/L)) and/or;
b. Signs of pulmonary hyperperfusion (prolonged ventilator
dependency).
AND
III. Echocardiographic findings of significant ductal left-to-right
shunting
a. Diameter of PDA > 1.5 mm, and;
b. Unrestricted ductal left-to-right shunting (‘pulsatile pattern’):
end-diastolic flow velocity < 50% of peak flow velocity, and/or;
c. End-diastolic flow velocity left pulmonary artery > 0.3 m/s,
and/or;
d. Left atrial to aortic ratio > 1.5.
AND/OR
a. Severe left ventricular failure (mitral regurgitation), and/or;
b. Disturbed end-organ perfusion (retrograde diastolic blood
flow in descending aorta).
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Co-interventions
It is essential that neonatal management is similar in
both study arms except for the prescription of IBU and
routine echocardiography at the end of the drug
course(s) in the medical treatment arm. All patients in
this study will be treated according to current (inter)-
national guidelines and local protocols regarding neo-
natal intensive care management. When ductal closure
has not been documented before discharge, ductal pa-
tency is echocardiographically examined in both arms of
the study, when this is indicated by the local paediatric
cardiologist and only at a date after the primary out-
comes have been established, after a postmenstrual age
of 36 weeks. Echocardiographic pictures and movies are
stored and collected for blinded re-analysis at the end of
the study.
All prognostic relevant co-interventions and condi-
tions will be documented, using the standard medical re-
cords, such as (a) administration of antenatal steroids;
(b) maternal disease (e.g. pre-eclampsia); (c) maternal
medication, especially COXi; (d) mode of delivery; (e)
multiple birth; (f ) duration of rupture of membranes; (g)
GA at birth; (h) birth weight; (i) Apgar scores at 5min;
(j) umbilical blood gas analysis; (k) resuscitation after
birth; (l) surfactant administration, and; (m) postnatal
steroids.
Sample size, power and statistical methods
Sample size
Based on data from the Dutch Perinatal Registry the in-
cidence of our primary outcome measures mortality,
NEC and BPD is 20, 10 and 15% respectively in preterm
infants less than 28 weeks’ gestation [119].
Non-inferiority is defined as a significant difference in
the primary outcome parameter between the two arms
of less than 10%. In other words, the 95% confidence
interval of the observed difference between an expecta-
tive approach and COXi treatment should not exceed
the non-inferiority margin of 10%. With an estimated a
priori risk for the composite of mortality and/or NEC
and/or BPD at 36 weeks PMA of 35%, a one sided type I
error of 5% and a power of 80%, the sample size to ex-
clude a non-inferiority margin of 10% for the difference
of proportion of participants reaching the primary out-
come parameter is 564 patients, being 282 patients in
each arm. This sample size was calculated using PASS
2008, version 08.0.8 NCSS.
Time frame
Based on retrospective data a total of 540 preterm neo-
nates with a GA less than 28 weeks will be born yearly
in The Netherlands, of whom approximately 270 (50%)
will have a PDA at a PNA of 24–72 h. With an
estimated inclusion rate of 66% (n = 178), patient recruit-
ment will take approximately 3 years.
Data analysis
Treatment effects for the dichotomous clinical outcomes
will be reported using risk differences with 95%
confidence interval. Normally distributed data will be
presented as mean ± standard deviations, uneven distrib-
uted data as medians with interquartile ranges. Categor-
ical data will be analysed using the Chi-square for two-
and multiway tables. Continuous data will be analysed
using the Student’s t test. Both intention-to-treat and
per-protocol analyses will be employed. Statistical sig-
nificance is defined as a p-value < 0.05. For the primary
outcome a 95% one sided confidence interval for the risk
difference will be calculated and when based on this
interval a difference of 10% or more can be excluded,
non-inferiority will be concluded.
Adverse events and monitoring
Data safety monitoring board
An external Data Safety Monitoring Board (DSMB) will
monitor the safety, validity, and credibility of the trial in
order to protect the patients and will provide the trial’s
Steering Committee with recommendations regarding
continuation or cessation of the trial. The normal distri-
bution between the components of the primary outcome
parameter will be closely monitored by the DSMB. The
DSMB is composed of three individuals: a neonatologist
with extensive knowledge about PDA, a statistician who
has experience with clinical trials and a paediatric cardi-
ologist with extensive knowledge about neonatal haemo-
dynamics. The composition, tasks, responsibilities and
working procedures of the DSMB are described in a
charter. The DSMB will meet to discuss the findings of
the safety interim analyses. These will be conducted
when 15, 30, 50 and 75% of the data have been gathered.
The DSMB charter states that there are two possible
reasons for stopping the study early, namely concerns
for safety and futility. In principle, the trial will not be
stopped early before the minimum number of evaluable
patients required (n = 564) are included for beneficial ef-
fect of IBU treatment on the primary outcome. Unless
there is an unacceptably high rate of mortality in either
the IBU or expectative group, this is to preserve the
power for evaluation of neurodevelopmental outcome at
2 years corrected age. Hence, the interim analyses will
not be associated with alpha spending.
Reporting adverse events
Adverse events are defined as any undesirable experi-
ence occurring to a subject during the study, whether or
not considered related to the interventions in this study.
All adverse events observed by the parents, caretakers or
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the investigator and staff will be recorded in the eCRF
until discharge home.
A serious adverse event (SAE) is any untoward med-
ical occurrence or effect that at any dose (a) results in
death; (b) is life threatening (at the time of the event);
(c) requires hospitalization or prolongation of existing
inpatients’ hospitalization; (d) results in persistent or sig-
nificant disability or incapacity, and; (e) is a congenital
anomaly or birth defect (not applicable in this study).
Any other important medical event that may not result
in death, be life threatening, or require hospitalization,
may be considered a SAE when, based upon appropriate
medical judgement, the event may jeopardize the subject
or may require an intervention to prevent one of the
outcomes listed above. An elective hospital admission
will not be considered a SAE.
All SAEs will be reported, by the coordinating
principle investigator (PI) to the DSMB and through the
web portal ToetsingOnline to the accredited medical
ethics committee (MEC) that approved the protocol. In
non-Dutch centres the PI will report to the coordinating
PI in The Netherlands and to the relevant national au-
thorities. All adverse events will be followed until they
have abated, or until a stable situation has been reached.
SAEs need to be reported till end of study.
This study population has a high risk of serious com-
plications, which are inherent to their vulnerable condi-
tion and unrelated to the intervention which is under
evaluation in this trial, the so-called ‘context-specific
SAEs’. These are included in the primary and secondary
outcomes of this study and are recorded in the eCRF by
the PI. Immediate and individual reporting of all these
condition related complications will not enhance the
safety of the study, so they will be presented to the
DSMB and MEC once a year [120–122].
Current status of trial
The first patient has been included in the study in De-
cember 2016.
Discussion
A growing number of clinicians believe the PDA is an
innocent bystander, since no causal relationship has been
proven between a hsPDA and the risk of conditions re-
lated to pulmonary hyperperfusion (e.g. PH and BPD)
and/or systemic hypoperfusion (e.g. NEC). An expecta-
tive management is gaining interest, although convincing
evidence to support this management is lacking, since
there is no RCT available comparing treatment with an
expectative approach. We found only one small study de-
scribing a prospective cohort and several retrospective
studies comparing two or three time eras with comparison
of different management approaches in preterm infants
with a persistent PDA [81–89]. These observational
studies have not shown a concomitant increase in mortal-
ity and morbidity related to a decrease in active ductal
closure.
In this study we randomise preterm infants born at
less than 28 weeks’ gestation to two different intentions
regarding the management of a PDA. Our primary hy-
pothesis is that an expectative treatment is non-inferior
to early treatment of a PDA in premature infants born
at a GA less than 28 weeks. In the treatment arm the
PDA is regarded a plausible cause of neonatal mortality
and morbidity secondary to an increased pulmonary per-
fusion at the expense of systemic hypoperfusion, while
in the expectative management arm the PDA is accepted
as a non-pathological phenomenon and PDA is merely
regarded as a marker of immaturity. It was deliberately
chosen not to perform a placebo-controlled trial, be-
cause it is our conviction that then the focus would be
on treatment of a PDA in the study population with an
associated increased risk of open label treatment, as has
occurred in former RCTs. To further minimize the risk
of contamination of the expectative management group
we defined strict open label criteria.
We aim to gain more insight in the natural course of
the PDA in the expectative management arm. Therefore,
an echocardiogram, that is blinded for the attending
clinical team, is performed at the end of the first week.
This trial will be protected from selection bias by using
concealed, stratified and blocked randomisation. Patient
characteristics will be collected from all eligible infants
that are not included in this study in order to assess any
potential recruitment bias.
If this trial supports our hypothesis that an expectative
management is non-inferior to early closure, there will
be a reduction in costs, which will be calculated with the
CEA en BIA. Not only in this economic perspective an
expectative treatment would be more interesting, also
vulnerable premature infants will be prevented from
potential adverse effects from medical or surgical
treatment.
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